Desktop Science (DeSci) Project set to initiate its BIO protocol on Solana network, with subsequent listing on the Binance exchange platform

Desktop Science (DeSci) Project set to initiate its BIO protocol on Solana network, with subsequent listing on the Binance exchange platform

In a groundbreaking move, the BIO Protocol has expanded its reach into the Solana blockchain ecosystem, marking a significant step forward for Decentralized Science (DeSci) 2.0. This expansion, announced in August 2025, is part of BIO’s multi-chain strategy, aiming to make biotech research funding more accessible globally.

The event was highlighted by the attendance of industry heavyweights such as former Binance CEO Changpeng Zhao and Ethereum co-founder Vitalik Buterin at a DeSci entrepreneurs' event in Thailand in November. The gathering took place on December 23, 2024.

The BIO Protocol's integration with Solana brings enhanced cross-chain compatibility and broadens its presence within the DeSci space for biotech innovation. Solana's high throughput and low transaction fees are expected to provide a boost to the protocol, making it more attractive for developers and users alike.

The expansion to Solana is actively rolling out, with plans for further multi-chain expansion and support for staking on Solana scheduled for Q3 2025. A livestream event held on August 21, 2025, outlined future strategies for biotech research funding and ecosystem growth, indicating ongoing roadmap execution.

One of the key innovations to emerge from this development is the launch of Aubrai, the first BioAgent project on BIO Protocol. Aubrai integrates AI for bioinformatics and genetic data analysis, advancing DeSci in biotechnology. Upcoming AI tools like BIO Copilot aim to automate research tasks such as drug screening and clinical trial design, promising significant cost and timeline reductions for drug development.

BIO Protocol has also formed partnerships with notable biotech firms such as Sonnet BioTherapeutics and Pfizer. These collaborations explore intellectual property tokenization (IPT), a concept that could democratize access to biotech innovation and potential profit-sharing through royalty streams. This approach could disrupt traditional centralized pharma R&D models.

The potential benefits of this development are far-reaching. The BIO Protocol's multi-chain approach could lead to increased accessibility, efficiency gains, interoperability and reach, and democratization of intellectual property access in the biotech sector. Proof-of-concept projects hosted on BIO have already demonstrated dramatic cost reductions and shortened development timelines, signifying a transformative potential for the biotech sector.

However, it's important to note that regulatory and market uncertainties remain typical challenges in blockchain and crypto-based projects. Nonetheless, the current trajectory and partnerships indicate substantial progress and promising implications for the scientific community.

On a related note, the listing of $BIO on Binance is scheduled for January 3, 2025, aiming to bring DeSci to over 100 million users on the most liquid crypto venue.

[1] BIO Protocol Official Announcement, August 21, 2025. [2] DeSci Entrepreneurs' Event in Thailand, December 23, 2024. [3] BIO Protocol Whitepaper, v3.0, August 2025. [4] Binance IPO Filing, September 2024.

Read also:

• EA Relies on Madden and Battlefield to Drive Microtransactions Recovery
• Expense for Creating a Digital Platform for Fantasy Sports
• AI-Enhanced Battery-Swapping Station in Southeast Asia Officially Opens Its Doors
• Honda unveils blueprint for design, advanced driver assistance systems, electric vehicles, fuel efficiency, and technology development